row-start col-xs-12 colour-section row-end |
We have gathered together delegates from across the Midlands region who are keen to collaborate and work with international companies and organisations. Further details can be found below:
Nicholas Barnes, CEO
Catherine Brady, Chief Operating Officer
Visit: www.celentyx.com
Email: catherine.brady@celentyx.com
Tel: (+44) 7725 963391
Company Profile:
Celentyx is a CRO providing bespoke drug discovery services focused on human immunology across a range of therapeutic areas, including immuno-oncology, autoimmunity, inflammation, fibrosis and neuroinflammation and are highly experienced in developing and providing assays using human primary cells accross drug discovery.
Close to major hospitals and blood services (established alliances), assays are performed using blood and tissue from healthy volunteers and patients with defined disease, with access to clinical records.
Celentyx has well-established assay platforms in multi-colour flow-cytometry, CyTOF, high-content-imaging, multiplex supernatant analysis (Luminex), super-resolution-microscopy plus proteomic and molecular biology capability, enabling high-resolution analysis of the human immune system for target discovery, screening, candidate selection, MoA, and biomarker studies. UK-based, Celentyx has supported pharma/Bio-Tech companies for nearly two decades. Along with internationally recognised scientists within the company, Celentyx benefits from partnerships with the world-leading expertise of translational medicine departments at the Universities of Oxford and Birmingham.
Currently exports to:
Spain: No
Portual: No
Follow us:
LinkedIn: www.linkedin.com/company/5171741
Back to Top
Linos Lazarides, Senior Business Development Manager
Visit: www.charnwood-molecular.com
Email: l.lazarides@charnwood-molecular.com
Tel: (+44) 7949 323309
Company Profile:
Charnwood Molecular is an integrated drug discovery provider (Chemistry, Biology, Computational Chemistry, DMPK & PR&D), with a 25-year track record of delivery to our clients worldwide. We believe in bringing together the right experts, technologies, and capabilities, to support customer drug discovery projects and deliver potent and selective drug-like candidates.
Our experienced project scientists understand the drug discovery process with expertise in all major disease areas and targets. Our world-class laboratory facility at Charnwood Campus, is the single location of all our services. This enables fast and seamless progression along the drug discovery time.
Since our inception we have successfully supported hundreds of life science groups globally, from academic groups to biotechnology and pharmaceutical companies. We place great emphasis on open collaboration in our client relationships.
What makes Charnwood Molecular unique is our unwavering passion for the truly ground-breaking science we facilitate and the trusting relationships we build.
Currently exports to:
Spain: No
Portual: No
Follow us:
LinkedIn: www.linkedin.com/company/charnwood-molecular/mycompany
Back to Top
Mike Fisher, Vice President & Head of Business Development
Visit: www.Oncimmune.com
Email: mike.fisher@oncimmune.com
Tel: (+44) 7870 904709
Company Profile:
Oncimmune is a pioneer in the use of autoantibodies as one of the earliest signals of disease.
ImmunoINSIGHTS™, our best-in-class antibody biomarker discovery engine utilises one of the world’s largest antigen libraries, covering over 8000 human antigens to profile antibodies from biologic samples in very low volume (50 µl) using Luminex xMAP®. We offer high content biological insights and analytics powered by proprietary machine learning algorithms, models and deep knowledge mining solutions.
Oncimmune’s core biomarker technology and expertise in the immune system enables life-science organisations to understand the immune response to disease and its treatment. ImmunoINSIGHTS can be used to:
• Stratify patients into clinically relevant sub-groups
• Predict response to treatment and immune-related adverse events (irAEs)
• Characterise the disease state and define the disease
• Understand the immune response to disease
• Detect treatment-specific immune excitation
• Predict off-target effects and non-specific binding of therapeutic antibodies
Currently exports to:
Spain: Yes
Portual: Yes
Follow us:
Twitter: www.twitter.com/oncimmuneECDT LinkedIn: www.linkedin.com/company/oncimmune
Back to Top
Ed Hogarth, Business Development Associate
Visit: www.reachseparations.com
Email: e.hogarth@reachseparations.com
Tel: (+44) 07412020724
Company Profile:
Reach Separations specialises in chromatography for the analysis and purification of small molecules.
The latest HPLC and SFC technologies are used side by side for chiral and achiral separations to support our clients across the pharmaceutical, agrochemical and fine chemical sectors.
With facilities in the UK and France, we offer a viable and economical solution to purification challenges to clients across Europe and beyond.
Currently exports to:
Spain: Yes
Portual: No
Follow us:
Twitter: www.twitter.com/REACHSEPARATION LinkedIn: www.linkedin.com/company/reach-separations
Back to Top
Rachel Hemsley, Business Development Director
Visit: www.sygnaturediscovery.com
Email: info@sygnaturediscovery.com
Tel: (+44) 7950 530310
Company Profile:
Sygnature Discovery is a leading independent integrated drug discovery and pre-clinical services company. Private equity-backed, Sygnature operates fully-enabled research facilities at two sites in the United Kingdom and has an office in Cambridge, MA.
Our experienced drug hunters possess all the professional skills and know-how required to undertake the most demanding of drug discovery programs and accelerate them towards becoming drug candidates.
Sygnature has a great track record of success for its clients. Since 2011, we have delivered 30 compounds into pre-clinical development, 15 of which have subsequently entered the clinic (Phases I, II and III).
Currently exports to:
Spain: No
Portual: No
Follow us:
Twitter: www.twitter.com/SygnatureDiscov LinkedIn: www.linkedin.com/company/sygnature-discovery
Back to Top
row-start col-xs-12 video-section center row-end |